Published in Oncotarget on May 20, 2015
MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun (2015) 1.01
microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB. Oncotarget (2016) 0.82
Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations. Oncotarget (2016) 0.81
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer (2017) 0.80
A protein deep sequencing evaluation of metastatic melanoma tissues. PLoS One (2015) 0.77
The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol (2017) 0.75
Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells. Cell Biol Toxicol (2016) 0.75
DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. BMC Med Genomics (2015) 0.75
Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma. PLoS One (2017) 0.75
TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT. Nat Commun (2017) 0.75
Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation. Mol Carcinog (2016) 0.75
Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma. Medchemcomm (2016) 0.75
NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. Mol Oncol (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Adjustment of systematic microarray data biases. Bioinformatics (2004) 5.22
An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (2011) 4.02
Cutaneous melanoma. Lancet (2005) 3.94
Melanocytes and the microphthalmia transcription factor network. Annu Rev Genet (2004) 3.78
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov (2014) 2.51
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A (2009) 2.32
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol (2012) 2.17
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun (2014) 2.10
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol (2013) 2.08
Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res (2010) 2.01
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 1.89
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol (2014) 1.55
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun (2014) 1.48
Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res (2009) 1.40
Molecular profiling reveals low- and high-grade forms of primary melanoma. Clin Cancer Res (2012) 1.17
Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res (2008) 1.17
The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol (2013) 1.07
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer (2014) 0.93
Monitoring of technical variation in quantitative high-throughput datasets. Cancer Inform (2013) 0.91
The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition. Breast Cancer Res (2012) 0.91
Molecular and genetic diversity in the metastatic process of melanoma. J Pathol (2014) 0.86
Developmental pathways activated in melanocytes and melanoma. Arch Biochem Biophys (2014) 0.84
A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol (2012) 0.84
Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. J Invest Dermatol (2015) 0.88
Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication. Clin Genet (2017) 0.75